Mechanisms of Immune Recognition of Engineered Therapeutic Cells

Abstract

The clinical application of engineered therapeutic cells, such as CAR-T cells and stem cell-based therapies, has transformed the landscape of modern medicine. However, the host immune system's ability to recognize and respond to these engineered cells remains a critical determinant of therapeutic success or failure. This review comprehensively examines the mechanisms underlying immune recognition of engineered therapeutic cells, synthesizes the latest research findings, and discusses clinical implications for optimizing efficacy and safety. The discussion spans innate and adaptive immune responses, the role of immunogenic antigens, and strategies to modulate immune recognition, providing evidence-based insights for clinicians and researchers alike.

Introduction

Engineered therapeutic cells have revolutionized the treatment of various malignancies, genetic disorders, and degenerative diseases. Technologies such as chimeric antigen receptor T (CAR-T) cells, genetically modified stem cells, and induced pluripotent stem cell (iPSC) products offer targeted and durable therapeutic potential. Despite these advances, the immune system's capacity to recognize and reject or modify the function of these cells poses a significant challenge to their clinical application. Understanding the complex interplay between engineered cells and host immunity is essential for enhancing therapeutic outcomes while minimizing adverse immune-mediated events.

Epidemiology / Disease Burden

The use of engineered therapeutic cells has rapidly expanded, particularly in hematological malignancies and rare genetic disorders. For instance, CAR-T therapies have received FDA approval for refractory B-cell malignancies, offering new hope to patients with limited options. The global incidence of conditions targeted by cell therapies, such as relapsed acute lymphoblastic leukemia and large B-cell lymphoma, underscores the urgent need for effective and durable interventions. Nevertheless, immune-mediated rejection or dysfunction of infused cells contributes to treatment failures, relapse, or adverse effects, highlighting the importance of immune recognition mechanisms in determining disease burden and therapeutic outcomes.

Pathophysiology

Immune recognition of engineered therapeutic cells involves multiple, interdependent mechanisms. Innate immune responses are mediated by natural killer (NK) cells, macrophages, and complement activation, targeting non-self or stress-induced markers on engineered cells. Adaptive immunity, particularly T- and B-cell responses, is triggered by the presentation of neoantigens or allogeneic antigens introduced during genetic engineering. The expression of non-human sequences (e.g., murine-derived CAR constructs), aberrant glycosylation patterns, and residual undifferentiated cells can enhance immunogenicity. Furthermore, antigen-presenting cells (APCs) can process and present engineered cell-derived peptides, priming effector lymphocytes and perpetuating immune responses, thus impacting cell persistence and function.

Risk Factors

Several risk factors increase the likelihood of immune recognition and elimination of engineered therapeutic cells. These include mismatched human leukocyte antigen (HLA) expression between donor and recipient, the use of non-human or synthetic gene sequences, insufficient immunosuppression, and prior alloimmunization from transfusions or transplants. Additionally, the source and differentiation state of the therapeutic cells, as well as the presence of viral vectors or residual undifferentiated cells, can elevate immunogenic potential. Patient-specific factors such as immune competence, age, underlying disease burden, and prior exposure to immunomodulatory therapies further modulate risk.

Clinical Features

Immune-mediated rejection or modification of engineered therapeutic cells manifests as loss of cell persistence, diminished therapeutic function, or adverse immune reactions. Clinically, this may present as early or late relapse (e.g., in CAR-T therapy), development of anti-drug antibodies, cytokine release syndrome, or graft-versus-host disease (GVHD) in allogeneic settings. Subclinical immune responses may also impair long-term engraftment or lead to low-level, chronic inflammation, affecting overall outcomes and necessitating close clinical monitoring.

Diagnosis

Evaluation of immune recognition involves both laboratory and clinical assessments. Flow cytometry and molecular assays quantify persistence and phenotype of infused cells. Detection of anti-drug antibodies, assessment of cytokine profiles, and monitoring for donor-specific HLA antibodies provide further evidence of immune engagement. Tissue biopsies and immunohistochemical analyses can reveal immune cell infiltration or rejection phenomena. Advanced omics approaches, including single-cell RNA sequencing, are increasingly used to characterize immune-cell interactions at high resolution, aiding in early detection and risk stratification.

Treatment & Management

Management strategies aim to prevent or mitigate immune-mediated rejection while preserving therapeutic efficacy. Approaches include pre-infusion lymphodepletion to reduce host immunity, the use of immunosuppressive agents (e.g., corticosteroids, calcineurin inhibitors), and selection of less immunogenic cell products. Engineering tactics such as HLA-matching, knockout of immunogenic antigens (e.g., β2-microglobulin), and expression of immune-evasive molecules (e.g., PD-L1) have shown promise. In cases of overt rejection, escalation of immunosuppression or re-infusion of modified cells may be considered, along with supportive care for associated complications.

Recent Advances / Emerging Therapies

Recent advances in genome editing, cell engineering, and immunomodulation have expanded the therapeutic window for engineered cells. CRISPR/Cas9 and other gene-editing tools facilitate precise deletion of immunogenic epitopes, while synthetic biology approaches enable the design of stealth or universal donor cells. The development of hypoimmunogenic iPSCs and CAR-T cells lacking HLA expression represents a promising frontier, potentially enabling off-the-shelf products with reduced rejection risk. Novel checkpoint inhibitors and tolerogenic regimens are under investigation to promote immune tolerance without compromising antitumor or regenerative efficacy. Multi-omics profiling and systems immunology are providing deeper insights into host-cell interactions, guiding the development of next-generation cell therapies.

Guideline Recommendations

Major guidelines, including those from the American Society of Hematology and European Society for Blood and Marrow Transplantation, recommend comprehensive preclinical immunogenicity testing and individualized risk assessment prior to therapeutic cell infusion. Protocols emphasize HLA-matching when feasible, monitoring for anti-cell immune responses, and ongoing surveillance for adverse immune events post-infusion. Multidisciplinary coordination among hematologists, immunologists, and laboratory specialists is essential for optimizing patient selection, minimizing risks, and managing complications in accordance with evolving best practices.

Conclusion

Immune recognition remains a central challenge in the clinical deployment of engineered therapeutic cells. A nuanced understanding of underlying mechanisms, patient- and product-specific risk factors, and the integration of innovative engineering and immunomodulatory strategies are critical for maximizing therapeutic success. Ongoing research and adherence to evidence-based guidelines will be paramount in refining these novel therapies, ensuring long-term safety, efficacy, and accessibility for diverse patient populations.